🔗 Share this article

As America proceeds with sweeping changes to its vaccine guidelines, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning COVID-19 vaccinations in the global health crisis and has zeroed in on alleged fatalities after Covid immunization in her recent position at the FDA.

Planned Changes to Pediatric Immunization Schedule

Public health authorities were set to reveal sweeping changes to the childhood vaccine schedule recently, bringing the US with the Danish national calendar, sources say – a major change that would put the US at odds with much of the world with little proof for benefit. This reveal has been postponed until the next year.

In place of the top vaccines chief, Dr. Høeg is set to address the audience at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to head the center this year.

Consolidating Power at the Agency

This interim role might represent a strengthened alliance between the drug and biologics branches as Dr. Høeg and Prasad consolidate power at the FDA – and it suggests a renewed priority upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for ending certain childhood shot schedules in the US in order to be more similar to the Danish model, a country with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – typically the domain of Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Questions Over Background

Høeg has little discernible track record in medication creation, approval processes or administrative roles, which has been typical for past leaders of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and CBER since March.

“She appears not to have any of the qualifications” for leading the CDER, remarked Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a sizeable institution. She is not an expert in drug approvals.”

Past commissioners of the center would “understand regulatory frameworks and the research of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she lacks the sort of resume that previous people who ran CBER have had.”

CDER has an immense workload at the FDA, she pointed out.

“Many people just focuses on the novel medication approvals, but the generic drug division authorizes a multitude of generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and every single one must be managed,” Dr. Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant management aspect to the role, which manages more than 5,000 employees. “It’s a huge leadership role, if you execute it properly,” Woodcock added.

Official Statement and Contentious Initiatives

In response to concerns about Høeg’s qualifications and whether this assignment signifies greater collaboration among agency officials on vaccines, a spokesperson responded that the “concerns are based on inaccurate presumptions”.

“Her resume matches the functions of her position,” the representative explained, pointing to the period Høeg spent guiding the agency head on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a contentious expedited medication authorization process that reportedly worried her predecessors. “How are these drugs being chosen for this fast-track system? Who takes the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the agency right now.”

In general, he said, “the FDA seems to be moving towards less stringent rules of pharmaceuticals, with the exception of shots.”

Documented Track Record on Immunizations

With vaccines, Dr. Høeg has a clearer, if troubling, history, critics have noted. She released a research paper using unverified volunteer-provided data to assess the incidence of myocarditis following Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Among her “policy goals” for the current government included changing rules for new vaccines and ending “optional” vaccines, she stated following the vote on a audio program. At the agency, Høeg has allegedly floated the idea of excluding teenage boys from obtaining COVID-19 vaccines.

“She’s an thorough dogmatist who begins with her conclusions and tailors the evidence to retrofit the science in a extremely disingenuous, dishonest way,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|